BioNTech SE previously disclosed that the Company was in discussions with the National Institutes of Health (NIH) concerning royalties and other amounts allegedly owed on sales of the Company's COVID-19 vaccine since commercialization, and that the NIH had delivered a communication threatening to send a notice of default under its license agreement with the Company. On March 22, 2024, the Company received a notice of default from the NIH relating to alleged amounts owed and breaches under such license. As previously disclosed, the Company disagrees with the positions being taken by the NIH, and intends to vigorously defend against all allegations of breach.